Roche's ($RHHBY) new set of HER2-positive breast cancer drugs is making it big with oncologists. Perjeta has already been prescribed by more than 85% of cancer docs, with twice as many patients per physician in treatment, on average, than 6 months ago. But it's Kadcyla, the company's new armed-antibody therapy, that's really on fire. Report